Allergy immunotherapy and inhibition of Th2 immune responses: A sufficient strategy?

Current Opinion in Immunology

Volumn 14, Issue 5, 2002, Pages 644-651

  Lewis, David B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ALLERGY; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; CLONAL ANERGY; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; REVIEW; RHINOCONJUNCTIVITIS; TH2 CELL;

EID: 0036773927     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00388-6     Document Type: Review

References (80)

1. Nawijn M.C., Dingjan G.M., Ferreira R., Lambrecht B.N., Karis A., Grosveld F., Savelkoul H., Hendriks R.W. Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation of a T1/ST2-expressing Th2- committed T cell compartment in vivo. J Immunol. 167:2001;724-732.
2. Finotto S., Neurath M.F., Glickman J.N., Qin S., Lehr H.A., Green F.H., Ackerman K., Haley K., Galle P.R., Szabo S.J., et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 295:2002;336-338. Mice with a selective gene disruption of T-bet spontaneously developed airway hyperreactivity, eosinophil and lymphocyte infiltration of the lungs, periairway collagen deposition, and increased levels of IL-4 and IL-13 in bronchial alveolar lavage fluid. This raises the possibility that T-bet might serve as a disease-modifying gene in human asthma.
3. Busse W.W., Lemanske R.F. Jr. Asthma. N Engl J Med. 344:2001;350-362.
4. Lambrecht B.N., De Veerman M., Coyle A.J., Gutierrez-Ramos J.C., Thielemans K., Pauwels R.A. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest. 106:2000;551-559.
5. Julia V., Hessel E.M., Malherbe L., Glaichenhaus N., O'Garra A., Coffman R.L. A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure. Immunity. 16:2002;271-283. Dendritic cells presenting peptide allergen were found to persist in the airways for up to eight weeks following aerosolization. This suggests a role for dendritic cells in antigen presentation to, and the activation of, Th2 cells during chronic allergic disease, in addition to their importance in initiating immune responses by naïve T cells.
6. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol. 107:2001;9-18.
7. Moverare R., Elfman L., Vesterinen E., Metso T., Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP Systemtrade mark. Allergy. 57:2002;423-430.
8. Kagi M.K., Wuthrich B. Different methods of local allergen-specific immunotherapy. Allergy. 57:2002;379-388.
9. Hoyne G.F., Tan K., Corsin-Jimenez M., Wahl K., Stewart M., Howie S.E., Lamb J.R. Immunological tolerance to inhaled antigen. Am J Respir Crit Care Med. 162:2000;S169-S174.
10. Sato M.N., Fusaro A.E., Victor J.R., Oliveira C.R., Futata E.T., Maciel M., Carvalho A.F., Duarte A.J. Oral tolerance induction in dermatophagoides pteronyssinus-sensitized mice induces inhibition of IgE response and upregulation of TGF-beta secretion. J Interferon Cytokine Res. 21:2001;827-833.
11. + T cell population rather than a Th2 effector population.
12. Nopp A., Hallden G., Lundahl J., Johansson E., Vrtala S., Valenta R., Gronneberg R., Van Hage-Hamsten M. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol. 106:2000;101-109.
13. Akdis C.A., Blaser K. Role of IL-10 in allergen-specific immunotherapy and normal response to allergens. Microbes Infect. 3:2001;891-898.
14. Gabrielsson S., Soderlund A., Paulie S., van der Pouw Kraan T.C., Troye-Blomberg M., Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy. 56:2001;293-300.
15. Eusebius N.P., Papalia L., Suphioglu C., McLellan S.C., Varney M., Rolland J.M., O'Hehir R.E. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post- allergen-specific immunotherapy. Int Arch Allergy Immunol. 127:2002;234-244.
16. Nasser S.M., Ying S., Meng Q., Kay A.B., Ewan P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol. 31:2001;3704-3713.
17. Durham S.R., Varney V.A., Gaga M., Jacobson M.R., Varga E.M., Frew A.J., Kay A.B. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 29:1999;1490-1496.
18. Wilson D.R., Irani A.M., Walker S.M., Jacobson M.R., Mackay I.S., Schwartz L.B., Durham S.R. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 31:2001;1705-1713.
19. Wilson D.R., Nouri-Aria K.T., Walker S.M., Pajno G.B., O'Brien F., Jacobson M.R., Mackay I.S., Durham S.R. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 107:2001;971-976.
20. Platts-Mills T.A., Vaughan J., Squillace S., Woodfolk J., Sporik R. Sensitization, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 357:2001;752-756. Exposure to cat allergen in children who did not become cat allergen-sensitized or asthmatic was associated with high allergen-specific IgG4 to IgE ratio. This finding is similar to what is observed in successful SIT, suggesting that it represents a form of tolerance to allergen.
21. von Garnier C., Astori M., Kettner A., Dufour N., Heusser C., Corradin G., Spertini F. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol. 30:2000;1638-1645.
22. Astori M., von Garnier C., Kettner A., Dufour N., Corradin G., Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol. 165:2000;3497-3505.
23. Jarnicki A.G., Tsuji T., Thomas W.R. Inhibition of mucosal and systemic T(h)2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1. Int Immunol. 13:2001;1223-1231.
24. Haselden B.M., Kay A.B., Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol. 122:2000;229-237.
25. Haselden B.M., Larche M., Meng Q., Shirley K., Dworski R., Kaplan A.P., Bates C., Robinson D.S., Ying S., Kay A.B. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 108:2001;394-401.
26. Oldfield W.L., Kay A.B., Larche M. Allergen-derived T cell peptide induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol. 167:2001;1734-1739. Intradermal administration of cat allergen (Fel d 1)-derived peptides in asthmatics resulted in decreased proliferation and Th2 cytokine production by peripheral blood mononuclear cells to the peptide or to whole allergen protein, suggesting the induction of a regulatory T cell population. These decreased responses persisted for up to 40 weeks, suggesting the therapeutic potential of peptide therapy.
27. Banerjee B., Kanitpong K., Fink J.N., Zussman M., Sussman G.L., Kelly K.J., Kurup V.P. Unique and shared IgE epitopes of Hev b 1 and Hev b 3 in latex allergy. Mol Immunol. 37:2000;789-798.
28. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med. 6:2000;1176-1182.
29. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., Tsai M., Galli S.J., Steinman L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol. 2:2001;216-222.
30. Janssen E.M., van Oosterhout A.J., van Rensen A.J., van Eden W., Nijkamp F.P., Wauben M.H. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol. 164:2000;580-588.
31. Verhoef A., Lamb J.R. Threshold signaling of human Th0 cells in activation and anergy: modulation of effector function by altered TCR ligand. J Immunol. 164:2000;6034-6040.
32. Woodfolk J.A., Sung S.S., Benjamin D.C., Lee J.K., Platts-Mills T.A. Distinct human T cell repertoires mediate immediate and delayed-type hypersensitivity to the Trichophyton antigen, Tri r 2. J Immunol. 165:2000;4379-4387.
33. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 6:2000;1167-1175.
34. Singh B., Read S., Asseman C., Malmstrom V., Mottet C., Stephens L.A., Stepankova R., Tlaskalova H., Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol Rev. 182:2001;190-200.
35. Suto A., Nakajima H., Kagami S.I., Suzuki K., Saito Y., Iwamoto I. Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am J Respir Crit Care Med. 164:2001;680-687.
36. Zhang X., Izikson L., Liu L., Weiner H.L. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol. 167:2001;4245-4253.
37. Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 192:2000;1213-1222.
38. Roncarolo M.G., Levings M.K., Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 193:2001;F5-9.
39. Martin P., Del Hoyo G.M., Anjuere F., Arias C.F., Vargas H.H., Fernandez-L A., Parrillas V., Ardavin C. Characterization of a new subpopulation of mouse CD8alpha(+) B220(+) dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood. 100:2002;383-390.
40. + T cells that preferentially produced IL-10, but neither Th1 or Th2 cytokines, were generated from naïve cells by priming in the presence of immunosuppressive drugs (glucocorticoids and 1,25(OH)2-vitamin D3 and antibodies that neutralize both Th1 and Th2 cytokines). This suggests the potential for certain forms of immunosuppression to induce regulatory T cell populations in vivo that might useful in suppressing Th2 disease (see [41••] ).
41. + T cell proliferation and IgE production in an IL-10-dependent manner. As Tr1 clones can be readily generated in humans (see [40•] ), this suggests the potential of this cell population for the immunotherapy of atopy.
42. Moore K.W., de wall Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19:2001;683-765. A comprehensive and very useful review of the molecular biology and immunology of IL-10 and its receptor.
43. D'Amico G., Frascaroli G., Bianchi G., Transidico P., Doni A., Vecchi A., Sozzani S., Allavena P., Mantovani A. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol. 1:2000;387-391.
44. Makela M.J., Kanehiro A., Borish L., Dakhama A., Loader J., Joetham A., Xing Z., Jordana M., Larsen G.L., Gelfand E.W. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci USA. 97:2000;6007-6012.
45. van Scott M.R., Justice J.P., Bradfield J.F., Enright E., Sigounas A., Sur S. IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice. Am J Physiol Lung Cell Mol Physiol. 278:2000;L667-L674.
46. Justice J.P., Shibata Y., Sur S., Mustafa J., Fan M., Van Scott M.R. IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice. Am J Physiol Lung Cell Mol Physiol. 280:2001;L363-L368.
47. Yang X., Wang S., Fan Y., Han X. IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reaction. Eur J Immunol. 30:2000;382-391.
48. Nakao A., Miike S., Hatano M., Okumura K., Tokuhisa T., Ra C., Iwamoto I. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 192:2000;151-158.
49. Hansen G., McIntire J.J., Yeung V.P., Berry G., Thorbecke G.J., Chen L., DeKruyff R.H., Umetsu D.T. CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 105:2000;61-70.
50. Gorelik L., Fields P.E., Flavell R.A. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 165:2000;4773-4777.
51. HayGlass K.T., Gangur V., Campbell J.D., Simons F.E. Experimental approaches to analysis of immune dysregulation in human allergic disease. Immunopharmacology. 48:2000;283-290. A useful review, making the case that Th1 responses to allergens are the normal response in nonatopics and are therefore a major goal for allergy immunotherapy.
52. Yssel H., Lecart S., Pene J. Regulatory T cells and allergic asthma. Microbes Infect. 3:2001;899-904. A useful review that argues that the induction of tolerance by regulatory T cells, rather than a Th1 response, is the normal response in nonatopics to allergen exposure and is, therefore, the appropriate goal of immunotherapy for atopy.
53. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12:2001;53-72.
54. Spergel J.M., Mizoguchi E., Oettgen H., Bhan A.K., Geha R.S. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest. 103:1999;1103-1111.
55. Hofstra C.L., Van Ark I., Hofman G., Nijkamp F.P., Jardieu P.M., Van Oosterhout A.J. Differential effects of endogenous and exogenous interferon-gamma on immunoglobulin E, cellular infiltration, and airway responsiveness in a murine model of allergic asthma. Am J Respir Cell Mol Biol. 19:1998;826-835.
56. Tsitoura D.C., Blumenthal R.L., Berry G., Dekruyff R.H., Umetsu D.T. Mechanisms preventing allergen-induced airways hyperreactivity: role of tolerance and immune deviation. J Allergy Clin Immunol. 106:2000;239-246.
57. Tsitoura D.C., Kim S., Dabbagh K., Berry G., Lewis D.B., Umetsu D.T. Respiratory infection with influenza A virus interferes with the induction of tolerance to aeroallergens. J Immunol. 165:2000;3484-3491.
58. Salvi S.S., Babu K.S., Holgate S.T. Is asthma really due to a polarized T cell response toward a helper T cell type 2 phenotype? Am J Respir Crit Care Med. 164:2001;1343-1346.
59. Castro M., Chaplin D.D., Walter M.J., Holtzman M.J. Could asthma be worsened by stimulating the T-helper type 1 immune response? Am J Respir Cell Mol Biol. 22:2000;143-146.
60. Walter M.J., Kajiwara N., Karanja P., Castro M., Holtzman M.J. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med. 193:2001;339-351.
61. Bryan S.A., O'Connor B.J., Matti S., Leckie M.J., Kanabar V., Khan J., Warrington S.J., Renzetti L., Rames A., Bock J.A., et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2000;2149-2153.
62. Hopfenspirger M.T., Agrawal D.K. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol. 168:2002;2516-2522.
63. Arkwright P.D., David T.J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol. 107:2001;531-534.
64. Shirtcliffe P.M., Easthope S.E., Cheng S., Weatherall M., Tan P.L., Le Gros G., Beasley R. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Respir Crit Care Med. 163:2001;1410-1414.
65. Gruber C., Kulig M., Bergmann R., Guggenmoos-Holzmann I., Wahn U. Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early Bacille Calmette-Guerin-vaccinated and nonvaccinated children. Pediatrics. 107:2001;E36.
66. lowand inhibit allergen-induced airway eosinophilia. This inhibition may be mediated by IL-10 and TGF-β rather than the induction of a Th1 response.
67. Horner A.A., Van Uden J.H., Zubeldia J.M., Broide D., Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev. 179:2001;102-118.
68. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
69. Serebrisky D., Teper A.A., Huang C.K., Lee S.Y., Zhang T.F., Schofield B.H., Kattan M., Sampson H.A., Li X.M. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol. 165:2000;5906-5912.
70. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Spiegelberg H.L., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 106:2000;124-134.
71. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T., Shirato K., Tamura G. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol. 167:2001;66-74.
72. Broide D.H., Stachnick G., Castaneda D., Nayar J., Miller M., Cho J.Y., Roman M., Zubeldia J., Hyashi T., Raz E. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol. 21:2001;175-182.
73. Coyle A.J., Lehar S., Lloyd C., Tian J., Delaney T., Manning S., Nguyen T., Burwell T., Schneider H., Gonzalo J.A., et al. The CD28-related molecule ICOS is required for effective T cell- dependent immune responses. Immunity. 13:2000;95-105.
74. Gonzalo J.A., Tian J., Delaney T., Corcoran J., Rottman J.B., Lora J., Al Garawi A., Kroczek R., Gutierrez-Ramos J.C., Coyle A.J. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol. 2:2001;597-604. This study suggests the feasibility of markedly reducing Th2-mediated immune responses and allergic pulmonary disease by blockade of ICOS/B7h interactions using either neutralizing antibodies or soluble ICOS-Fc domain fusion protein.
75. Dong C., Juedes A.E., Temann U.A., Shresta S., Allison J.P., Ruddle N.H., Flavell R.A. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409:2001;97-101.
76. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., Taylor A.F., Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 108:2001;E36.
77. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., McAlary M., Fowler-Taylor A., Racine A., Gupta N., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. J Am Med Assoc. 286:2001;2956-2967.
78. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., Agosti J.M. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 107:2001;963-970.
79. Mattes J., Yang M., Siqueira A., Clark K., MacKenzie J., McKenzie A.N., Webb D.C., Matthaei K.I., Foster P.S. IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung. J Immunol. 167:2001;1683-1692. This study suggests the existence of an alternative functional IL-13 receptor that does not require the IL-4 receptor α chain. Such a pathway might also explain the limited efficacy of sIL-4Rα in the treatment of asthma in humans (see [78] ), as IL-13 is likely to be an important contributor to allergic disease.
80. Dabbagh K., Xiao Y., Smith C., Stepick-Biek P., Kim S.G., Lamm W.J., Liggitt D.H., Lewis D.B. Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. J Immunol. 165:2000;3418-3422. vCCI a pox virus-derived protein that is a generic inhibitor of humans and rodent CC chemokines, blocked airway inflammation and airway hyper-reactivity in a mouse allergen-induced asthma model when given locally. This suggests that this protein, or a small molecule derivative, has potential for the local treatment of atopy and other inflammatory disease states.